Outcomes with intensive treatment for acute myeloid leukemia

Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcomes of patients with acute myeloid leukemia (AML). However, even before these innovations, outcomes with intensive chemotherapy had improved, which has not yet been extensively studied. Thus...

Descripción completa

Detalles Bibliográficos
Autores: Sobas, Marta Anna, Turki, Amin|||0000-0003-1347-3360, Villaverde Ramiro, Ángela|||0000-0002-7337-7218, Hernández-Sánchez, Alberto|||0000-0002-6601-3096, Martínez Elicegui, Javier|||0000-0001-5294-6162, González, Teresa, Melchor, R.A., Abáigar, María, Tur, L., Dall'Olio, Daniele, Sträng, E., Tettero, JM.|||0000-0002-0811-0824, Castellani, Gastone|||0000-0003-4892-925X, Benner, Axel|||0000-0002-7238-6956, Döhner, Konstanze|||0000-0002-2261-9862, Thiede, Christian|||0000-0003-1241-2048, Metzeler, Klaus H.|||0000-0003-3920-7490, Haferlach, T.|||0000-0003-0196-2837, Damm, Frederik, Ayala, Rosa|||0000-0002-2699-8353, Martínez-López, Joaquín|||0000-0001-7908-0063, Mills, Ken|||0000-0002-6362-4481, Sierra, Jorge|||0000-0002-7966-0356, Lehmann, Sylvain|||0000-0001-6117-562X, Della Porta, Matteo Giovanni|||0000-0002-6915-5970, Mayer, Jiří|||0000-0003-0567-9887, Reinhardt, Dirk, Villoria Medina, Rubén, Schulze-Rath, Renate, Barbus, Martje, Hernández Rivas, Jesús María|||0000-0002-9661-9371, Huntly, Brian|||0000-0003-0312-161X, Ossenkoppele, G., Döhner, Hartmut|||0000-0003-2116-5536, Bullinger, Lars|||0000-0002-5890-5510
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:322619
Acceso en línea:https://ddd.uab.cat/record/322619
https://dx.doi.org/urn:doi:10.3324/haematol.2024.285805
Access Level:acceso abierto
Palabra clave:Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Europe
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Prognosis
Treatment Outcome
Young Adult
Descripción
Sumario:Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcomes of patients with acute myeloid leukemia (AML). However, even before these innovations, outcomes with intensive chemotherapy had improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5,359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5-year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients <60 and ≥60 years old, and in those treated with and without consolidating allogeneic hematopoietic stem cell transplantation (alloHCT). While survival of AML elderly patients remains poor, patients ≥60 years old overall have a 20% survival benefit at 5 years if they receive an alloHCT. While further outcome improvement in intensively treated AML patients will likely be driven by targeted treatment approaches, this pan-European HARMONY dataset can serve as a multicenter comparator for future studies.

Similares en LA Referencia